GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » PS Ratio

COLL (Collegium Pharmaceutical) PS Ratio : 1.92 (As of Mar. 26, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Collegium Pharmaceutical's share price is $29.84. Collegium Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $15.55. Hence, Collegium Pharmaceutical's PS Ratio for today is 1.92.

Good Sign:

Collegium Pharmaceutical Inc stock PS Ratio (=1.94) is close to 1-year low of 1.86

The historical rank and industry rank for Collegium Pharmaceutical's PS Ratio or its related term are showing as below:

COLL' s PS Ratio Range Over the Past 10 Years
Min: 1.17   Med: 2.42   Max: 1132.94
Current: 1.94

During the past 12 years, Collegium Pharmaceutical's highest PS Ratio was 1132.94. The lowest was 1.17. And the median was 2.42.

COLL's PS Ratio is ranked better than
52.79% of 968 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs COLL: 1.94

Collegium Pharmaceutical's Revenue per Sharefor the three months ended in Dec. 2024 was $4.49. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $15.55.

During the past 12 months, the average Revenue per Share Growth Rate of Collegium Pharmaceutical was 15.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 32.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 14.80% per year.

During the past 12 years, Collegium Pharmaceutical's highest 3-Year average Revenue per Share Growth Rate was 399.90% per year. The lowest was -7.50% per year. And the median was 23.95% per year.

Back to Basics: PS Ratio


Collegium Pharmaceutical PS Ratio Historical Data

The historical data trend for Collegium Pharmaceutical's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical PS Ratio Chart

Collegium Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 2.77 1.69 2.27 1.83

Collegium Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.27 3.15 2.52 2.86 1.83

Competitive Comparison of Collegium Pharmaceutical's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's PS Ratio distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's PS Ratio falls into.



Collegium Pharmaceutical PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Collegium Pharmaceutical's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=29.84/15.553
=1.92

Collegium Pharmaceutical's Share Price of today is $29.84.
Collegium Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.55.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Collegium Pharmaceutical  (NAS:COLL) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Collegium Pharmaceutical PS Ratio Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Executives
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021